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The central nervous system (CNS) is an immunologi-
cally privileged site protected from uncontrolled ac-
cess of T cells by the blood-brain barrier (BBB),
which is breached upon autoimmune inflammation.
Here we have shown that receptor activator of nu-
clear factor-kB (NF-kB) ligand (RANKL) on T cells
regulates C-C type chemokine ligand 20 (CCL20)
production by astrocytes and T cell localization in
the CNS. Importantly, mice specifically lacking
RANKL in T cells were resistant to experimental auto-
immune encephalomyelitis (EAE) due to altered T cell
trafficking. Pharmacological inhibition of RANKL pre-
vented the development of EAE without affecting the
peripheral immune response, indicating that RANKL
is a potential therapeutic target for treating autoim-
mune diseases in the CNS.
INTRODUCTION
In vertebrates, the homeostatic transport of solutes and the traf-
ficking of lymphocytes into the central nervous system (CNS) are
controlled by the blood-brain barrier (BBB) (Ransohoff and En-
gelhardt, 2012). The BBB is a continuous, double-layered
boundary that surrounds the CNS. The vascular endothelium
of meningeal vessels and the brain choroid plexi form the
external layer of the BBB. The tight junctions sealing the endo-
thelium of meningeal vessels prevent the diffusion of cells and
large molecules from the blood into the cerebrospinal fluid
(CSF). The brain choroid plexi are anatomical structures sepa-
rating the peripheral blood from the CSF, constituted by a layer
of fenestrated epithelium selectively permeable to the cells of
the immune system (Ransohoff and Engelhardt, 2012). Astrocyte
endfeets and a proteic matrix form the internal, glial layer of the
BBB that surrounds the CNS parenchyma. The CSF, continu-1174 Immunity 43, 1174–1185, December 15, 2015 ª2015 Elsevier Inously secreted by the choroid plexi, fills the empty space be-
tween the endothelial and the glial barriers, flows through the
ventricular system inside the brain, through the subarachnoid
space around the brain and spinal cord, and then back to the
bloodstream. The CSF provides mechanical protection to the
CNS and is the transport medium for metabolites and cells of
the immune system.
Under physiological conditions, T cells enter into the CSF for
normal immune patrolling exclusively through the choroid plexus
fenestrated epithelium. Constitutive expression of the CCL20
chemokine on the choroid plexus drives recruitment of T cells
in a CCR6 chemokine-receptor-dependent manner (Reboldi
et al., 2009). However, in the presence of CNS inflammation,
the vascular endothelium of post-capillary meningeal vessels
might lose its barrier properties thus allowing the unselective
recruitment of leukocytes into the CNS (Reboldi et al., 2009).
T cells adhere to the activated vascular endothelium in an integ-
rin-dependent manner and transmigrate through the endothe-
lium ultimately reaching the CSF (Bauer et al., 2009; Laschinger
and Engelhardt, 2000; Rothhammer et al., 2011). T cells that
entered theCSF do notmigrate across the glial barrier to infiltrate
into the CNS parenchyma unless reactivated by resident anti-
gen-presenting cells (Bartholoma¨us et al., 2009). Only a few
molecules are known to regulate this process. Among these,
interleukin (IL)-17A has been reported to facilitate the infiltration
of T cells trough the glial layer of the BBB into the CNS paren-
chyma (Kang et al., 2010), yet the molecular mechanisms by
which T cells breach the two layers of the barrier are still largely
obscure.
Receptor activator of nuclear factor-kB (NF-kB) ligand
(RANKL), encoded by the Tnfsf11 gene, is expressed by mesen-
chymal cells of the bone controlling osteoclast differentiation
and bone remodeling (Kong et al., 1999). RANKL was originally
identified in activated T cells, which highly express on the cell
membrane (Anderson et al., 1997). It was later shown to have
many contradictory and ambiguous effects on the immune sys-
tem. Tnfsf11/ mice revealed an essential role for RANKL in
lymph node organogenesis (Kong et al., 1999) and in thec.
development of medullary thymic epithelial cells required for the
negative selection of autoreactive thymocytes (Akiyama et al.,
2008; Hikosaka et al., 2008). RANKL stimulates the survival, an-
tigen presentation, and cytokine production of in vitro differenti-
ated pro-inflammatory dendritic cells (DCs) expressing its recep-
tor RANK (Anderson et al., 1997; Josien et al., 2000; Wong et al.,
1997). Moreover, RANKL expressed on chronically activated
T cells expands a population of pro-inflammatory DCs in Il2/
mice, suggesting that RANKL enhances the immune response
(Ashcroft et al., 2003). On the other hand, overexpression of
RANKL in skin keratinocytes promotes the DC-mediated gener-
ation of regulatory T (Treg) cells (Loser et al., 2006). RANKL stim-
ulates induction of Treg cells and immune tolerance in mouse
models of oral tolerance and diabetes (Green et al., 2002; Wil-
liamson et al., 2002), clearly demonstrating that RANKL has im-
mune suppressive functions. However, the systemic blockade of
RANKL does not obviously affect the immune responses in mice
or humans (Bachmann et al., 1999; Cummings et al., 2009), sug-
gesting that RANKL plays a minor role in the host defense
against pathogens under physiological conditions.
Thus, the specific function of RANKL expressed by T cells in
the context of immune responses remains enigmatic and repre-
sents an immunological long-standing open question. The high
expression of RANKL on T helper-17 (Th17) cells (Sato et al.,
2006) led us to focus on Th17 cell-mediated autoimmunity.
Here we show that T cell-specific inactivation of RANKL inhibited
infiltration of T cells into the CNS and the development of exper-
imental autoimmune encephalomyelitis (EAE). RANKL expres-
sion on T cells induced the expression of CCL20 on astrocytes.
Astrocyte-specific deletion of RANK reduced the infiltration of
T cells in the spinal cord and markedly protected mice from
EAE. Pharmacological inhibition of RANKL using a small chemi-
cal compound was sufficient to suppress the development of
EAE. As such, we have identified an additional role of RANKL
in controlling T cell migration in the CNS and show that it might
be a therapeutic target for treatment of CNS autoimmunity.
RESULTS
T Cell-Specific Tnfsf11-Deficient Mice Are Protected
from EAE
In order to address the specific function of RANKL on T cells, we
generated T cell-specific Tnfsf11-deficient mice by crossing
Tnfsf11flox/D mice with the Lck-cre transgenic line (Nakashima
et al., 2011). The number of T cells expressing the RANKL protein
was greatly reduced in Tnfsf11flox/D Lck-cre, while T cells purified
from Tnfsf11flox/flox Lck-cremice still expressed RANKL albeit at
a reduced amount (Figures 1A and S1A). In our study, we thus
used the Tnfsf11flox/D Lck-cremice that have amuch higher dele-
tion efficiency. However, deletion of RANKL was specific to
T cells, since we did not observe any difference in RANKL
expression on other immune cells (Figure S1B). Tnfsf11flox/D
Lck-cre mice grew normally without any bone defects (Naka-
shima et al., 2011) and the numbers of conventional and plasma-
cytoid DCs were unaffected (Figures S1C and S1D), as in the
case of Tnfsf11/ mice (Kong et al., 1999). Tnfsf11flox/D Lck-
cremice had normal distribution and numbers of thymus-derived
regulatory T (tTreg) cells, peripherally derived Treg (pTreg) cells
(Figure S1E) and Th17 cells (Figure S1F) in the secondaryImmlymphoid organs. These data demonstrate that deletion of
RANKL from T cells has no major effects on the unperturbed im-
mune system.
Because Th17 cells express high amount of RANKL, we tested
its function in a Th17 cell-dependent experimental disease
model. We induced EAE, a model of autoimmune disease in
the central nervous system known to be dependent on Th17
cells (Zu´n˜iga et al., 2013), by immunization of Tnfsf11flox/D Lck-
cre mice with myelin oligodendrocyte glycoprotein 35-55
(MOG) peptide. Tnfsf11flox/D Lck-cre mice were markedly pro-
tected from the development of motor deficits (Figure 1B and
Table S1) up to 6 weeks after induction of EAE (Figures S2A
and S2B), and displayed decreased infiltration of inflammatory
cells in the spinal cord as well as decreased demyelination
compared to controls (Figures 1C and S2C). The numbers of
Th1 and Th17 cells in the spleen and lymph nodes of
Tnfsf11flox/D Lck-cre mice were comparable to control mice,
but T cells poorly infiltrated into the spinal cord (Figures 1D
and 1E). The frequency of Treg cells among total CD4+ T cells
was unchanged in all organs examined. However, the numbers
of CD4+ T cells and of Treg cells in the spinal cord were
decreased (Figures S2D–S2F). These findings indicate that
RANKL expression on T cells controls their ability to migrate to
the CNS. Throughout the course of EAE, RANKL modulated
T cell trafficking to the CNS rather than antigen presentation or
induction of peripheral Treg cells.
Autoimmune Inflammation in the Spinal Cord Is Inhibited
by T Cell-Specific Tnfsf11-Deficiency
We then checked the phenotype of Tnfsf11-deficient Th17 cells
and of the myeloid cells involved in the pathogenesis of EAE,
such as DCs, macrophages, and microglia. IL-17A production
and CCR6 expression were unaffected in Tnfsf11-deficient
T cells generated in vitro (Figure 2A) and isolated from the lymph
nodes of MOG-immunizedmice (Figure S3A). The frequency and
activation status of the DCs in the secondary lymphoid organs of
MOG-immunized Tnfsf11flox/D Lck-cremice were not changed in
comparison to control mice (Figures 2B and S3B). The frequency
of CD11chiMHC-II+ DCs (Figures 2B and 2C) and CD45hiF4/80+
inflammatory macrophages (Figures 2D and 2E) decreased
and the expression of pro-inflammatory cytokines was reduced
in the spinal cord of Tnfsf11flox/D Lck-cre mice (Figure 2F). Thus,
RANKL is dispensable for the normal development of Th17 cells
upon MOG immunization and does not affect the homeostasis
and activation of DCs in the secondary lymphoid organs, but
Tnfsf11-deficient T cells were unable to recruit or activate
effector cells in the CNS.
Tnfsf11-Deficient T Cells Fail to Transfer EAE
To test the ability of Tnfsf11-deficient T cells to migrate into the
CNS, we induced passive EAE (also called transfer EAE), in
which high numbers of peripherally injected encephalitogenic
T cells reach the CNS and induce the disease in recipient
mice (Arima et al., 2012). Equal numbers of cells isolated from
the secondary lymphoid organs of Tnfsf11flox/D Lck-cre and con-
trol MOG-immunized mice were injected into recipients after
in vitro restimulation with MOG peptide and IL-23. Tnfsf11-
deficient T cells normally differentiated into Th1 and Th17
cells in vitro (Figure S4A) and expressed normal amounts ofunity 43, 1174–1185, December 15, 2015 ª2015 Elsevier Inc. 1175
Figure 1. T Cell-Specific Tnfsf11-Deficient Mice Are Resistant to EAE
(A) RANKL expression on CD4+ T cells restimulated in vitro for 1 hr with PMA and ionomycin.
(B) EAE score (left) and incidence rate (right) of Tnfsf11flox/D Lck-cre mice (N = 18) and control littermates (N = 18).
(C) Pathological analysis of the spinal cord. Arrowheads indicate inflammatory cellular infiltrate (hematoxylin and eosin, HE) and demyelinated areas (Luxol fast
blue, LFB).
(D) Percentages of IFN-g and IL-17A producing cells amongCD4+ T cells in the lymph nodes, spleen, and spinal cords of MOG-immunizedmice. The dot plots are
gated on CD4+ T cells.
(E) Number of the indicated T cell subsets in the lymphoid organs as in (D). (Tnfsf11flox/D mice, N = 11; Tnfsf11flox/D Lck-cre mice, N = 12) The data are repre-
sentative of three ormore independent experiments. Mean ± SEMare shown. *p < 0.05; **p < 0.01; ***p < 0.005; NS, not significant. Please refer also to Figures S1
and S2.the Th1 and Th17 -specific chemokine receptors CXCR3 and
CCR6, respectively (Figure S4B). Consistent with these find-
ings, after restimulation, there was no difference in the percent-
ages of Th1 and Th17 cells between Tnfsf11-deficient and
control T cells (Figure 3A). We then checked the proliferative
capacity of T cells purified from the secondary lymphoid organs
of Tnfsf11flox/D Lck-creMOG-immunized mice. Tnfsf11-deficient1176 Immunity 43, 1174–1185, December 15, 2015 ª2015 Elsevier InT cells proliferated and survived as well as control cells in pres-
ence of MOG-loaded antigen presenting cells (APCs) in vitro
(Figures S4C and S4D). Nevertheless, adoptive transfer of
Tnfsf11-deficient T cells polarized in vitro under Th17 conditions
did not induce EAE (Figure 3B). Th1 and Th17 cells were barely
detectable in the spinal cord of mice injected with Tnfsf11-defi-
cient cells (Figures 3C and 3D) and infiltration of Treg cells wasc.
Figure 2. Tnfsf11-Deficient T Cells Inefficiently Induce Inflammation in the CNS
(A) Expression of CCR6 and IL-17A in CD4+ T cells activated for 5 hr with PMA and Ionomycin following 2 days in culture under Th17 polarizing conditions.
(B and C) Frequency (B) and numbers (C) of CD11c+MHC-II+ DCs in the indicated organs of Tnfsf11flox/D Lck-cre and control mice after MOG immunization.
(D and E) Frequency (D) and numbers (E) of F4/80+CD45dim microglial cells and F4/80+CD45hi macrophages in the spinal cord of MOG immunized animals.
(F) Expression of the Il6 and TnfmRNAs in the spinal cord of the immunizedmice. The data are representative of more than two independent experiments. Mean ±
SEM are shown. NR 4 mice per group. *p < 0.05; NS, not significant. Please refer also to Figure S3.almost completely suppressed (Figures 3D and 3E). Expression
of activation and proliferation markers on microglial cells
and recruitment of inflammatory macrophages were negligible
in mice that received Tnfsf11-deficient T cells (Figures 3D
and 3F).
Encephalitogenic T cells need restimulation by autoantigen-
presenting APC in the secondary lymphoid organs of recipient
mice to induce EAE. Two days after the adoptive transfer of
Th17 polarized T cells, the number and proliferation of Tnfsf11-
deficient T cells in the secondary lymphoid organs of congenic
recipient mice was comparable to that of control T cells (Figures
S4E–S4G). Tnfsf11flox/D Vav-icre CD4+ Th17 cells failed to infil-
trate into the spinal cord and to induce EAE upon adoptive trans-
fer into wild-type recipient mice (Figures S5A–S5C). Although
RANKL expression is much higher in Th17 than Th1 cells (Sato
et al., 2006), adoptive transfer of Tnfsf11-deficient T cells polar-
ized in vitro under Th1 condition did not efficiently induce EAE
(Figures S5D–S5F), suggesting that RANKL on Th1 cells might
also contribute to the lower EAE susceptibility of Tnfsf11flox/D
Lck-cre mice. Taken together, these results demonstrate that
expression of RANKL is essential for the migration of pathogenicImmT cells into the CNS and site-specific induction of autoimmune
inflammation.
Th17 Cells Stimulate Astrocytes to Produce CCL20
through RANK
To gain insight into the mechanism underlying the inability of
Tnfsf11-deficient T cells to breach the BBB, we analyzed the
expression of adhesion molecules and chemotactic factors in
Tnfsf11flox/D Lck cremice. In the presence of CNS inflammation,
T cells transmigrate through the endothelium of meningeal ves-
sels. Adhesion to endothelial VCAM-1 and ICAM-1 integrins via
integrin a4b1 is crucial for migration of T cells, as its blockade
or genetic inactivation prevents migration of T cells into the
CNS and induction of EAE (Engelhardt and Ransohoff, 2012; La-
schinger and Engelhardt, 2000; Ransohoff and Engelhardt, 2012;
Vajkoczy et al., 2001). In the MOG-immunized Tnfsf11flox/D Lck-
cre mice, Th17 cells in the lymph nodes expressed normal
amounts of a4 integrin (also called CD49d) and b1 integrin
(also called CD29) (Figure 4A). CD45CD31+ cells from the spinal
cord of the same animals normally expressed VCAM-1 and
ICAM-1 (Figure 4B). These findings show that expression ofunity 43, 1174–1185, December 15, 2015 ª2015 Elsevier Inc. 1177
Figure 3. Tnfsf11-Deficient T Cells Do Not Migrate to the CNS and Thus Fail to Induce EAE upon Adoptive Transfer
(A) Percentages of IL-17A, IFN-g, and CCR6 expressing CD4+ T cells isolated from the lymph nodes and spleen of MOG-immunized donor mice. The CD4+ T cells
were restimulated in vitro for 48 hr with MOG peptide-loaded APCs in the presence of IL-23 and then activated for 4.5 hr with PMA and Ionomycin.
(B) EAE score (left) and incidence (right) of Tnfsf11flox/D Lck-cre mice passively transferred with encephalitogenic T cells from donor mice of the indicated ge-
notype. N = 5 per group.
(C) Representative dot plots of the CD4+ T cells infiltrating into the spinal cord of the mice subjected to passive EAE in (B).
(D) Number CD4+ T cells and of the indicated CD4+ T cells subsets, F4/80+CD45dimmicroglial cells and F4/80+CD45hi macrophages in the spinal cords of themice
subjected to passive EAE in (B).
(E) Percentages of Treg cells and Treg markers in the spinal cord of the mice subjected to passive EAE in (B).
(F) Percentages of F4/80+CD45dimmicroglial cells and of F4/80+CD45hi macrophages in the spinal cords of the mice subjected to passive EAE in (B). The data are
representative of more than two independent experiments. Mean ± SEM are shown. *p < 0.05; NS, not significant. Please refer also to Figures S4 and S5.
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Figure 4. Tnfsf11-Deficient T Cells Ineffi-
ciently Induce CCL20 Production by Astro-
cytes
(A) Expression of a4 (CD49d) and b1 (CD29) in-
tegrins on IL-17A+CD4+ T cells in the lymph nodes
of mice 11 days after MOG immunization. Mean
fluorescence intensities are indicated within each
histograms. N = 5 mice per group.
(B) Expression of VCAM-1 and ICAM-1 on CD31+
CD45 endothelial cells in the spinal cord of the
mice 11 days after MOG immunization. Mean fluo-
rescence intensities are indicated within each his-
tograms. N = 5 mice per group.
(C) mRNA expression of chemokine ligands in the
spinal cord of the mice subjected to passive EAE by
transfer of T cells. Expression values were normal-
ized to b-actin. N = 5 per group.
(D) Expression of Ccl20 mRNA on each cell type in
the spinal cord of Tnfsf11flox/D Lck-cre and control
mice 12 days after the induction of active EAE.
(E) CCL20 production of wild-type (left) and
Tnfrsf11a/ (right) primary astrocytes co-cultured
with Th0 or Th17 cells from Tnfsf11flox/D or
Tnfsf11flox/D Lck-cre mice.
(F) EAE score of Tnfrsf11aflox/DGFAP-ERT2cremice
(N = 6) and Tnfrsf11aflox/+ GFAP-ERT2cre control
littermates (N = 4).
(G) Percentages of IFN-g and IL-17A producing
cells among CD4+ T cells, F4/80+CD45dim microglial
cells, and F4/80+CD45hi macrophages in the spinal
cord of the MOG-immunized mice shown in (F).
(H) Numbers of total CD4+ T cells and the indicated
CD4+ T cell subsets in the spinal cord of the mice
shown in (F).
(I) Expression of Ccl20 mRNA in the spinal cord
of of the mice shown in (F). The data are represen-
tative of more than two independent experiments.
Mean ± SEM are shown. *p < 0.05; **p < 0.01; ***p <
0.005; NS, not significant. The data are represen-
tative of more than two independent experiments.
Please refer also to Figure S6.
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RANKL on T cells does not affect the adhesive properties of
T cells and vascular endothelial cells, suggesting that interaction
of Tnfsf11-deficient T cells with the CNS vascular endothelium is
normal.
These results prompted us to examine the chemokines
involved in the recruitment of Th1 and Th17 cells to the spinal
cord parenchyma through the glial barrier during EAE. CXCL16
and CCL20, produced mainly by macrophages and astrocytes,
respectively, recruit Th1 and Th17 cells into the CNS (Ambrosini
et al., 2003; Fukumoto et al., 2004; Inoue et al., 2012; Kang et al.,
2010). The expression of Ccl20, but not Cxcl16 mRNA, was
markedly suppressed in the spinal cord of mice injected with
Tnfsf11-deficient T cells (Figure 4C). Considering that astrocytes
have been reported to express RANK (Hanada et al., 2009; Kim
et al., 2014), which is the receptor for RANKL, we hypothesized
that Th17 cells directly upregulated expression of CCL20 on as-
trocytes in a RANKL-dependent manner.
To this end, we sorted the main subpopulation of CNS-resi-
dent cells from the spinal cord of control and Tnfsf11flox/D Lck-
cre mice 12 days after the induction of EAE. Astrocytes sorted
from the spinal cord of control mice expressed the highest
amount of Ccl20, while astrocytes purified from Tnfsf11flox/D
Lck-cre did not (Figure 4D). We then assessed the ability of
RANKL on T cells to directly induce expression ofCcl20 on astro-
cytes in vitro. Coculture of Th17 cells with primary astrocytes
potently induced the secretion of CCL20 into the culture media,
albeit to a lesser extent than IL-1b, a well-known inducer of
CCL20 (Meares et al., 2012). This effect was not observed
when Th17 cells derived from Tnfsf11flox/D Lck-cre mice were
used (Figure 4E). Moreover, induction of CCL20 was severely
impaired when wild-type Th17 cells were cocultured with astro-
cytes isolated from Tnfrsf11a knockout mice, lacking RANK
expression (Figure 4E). These results show that expression of
RANKL on T cells stimulates astrocytes to produce CCL20 via
RANK signaling. Thus, the RANKL-RANK axis regulates the
migration of T cells through the glial barrier.
To specifically delete RANK on astrocytes, we utilized
Tnfrsf11aflox/D mice (Hanada et al., 2009) and transgenic mice
expressing cre under the control of an inducible glial fibrillary
acidic Protein (GFAP) promoter (GFAP-ERT2cre mice) (Ganat
et al., 2006). Tnfrsf11aflox/D GFAP-ERT2cre mice developed
EAE with reduced severity than Tnfrsf11aflox/+ GFAP-ERT2cre
control mice (Figures 4F and S6A). Infiltration T cells, in particular
TH1 cells, was reduced in the spinal cord of Tnfrsf11a
flox/DGFAP-
ERT2cre mice (Figures 4G and 4H), while the populations and
counts of Th1 and Th17 cells in the periphery were similar to con-
trols (Figures S6B and S6C). Importantly, expression of Ccl20
was reduced in the spinal cord of Tnfrsf11aflox/D GFAP-ERT2cre
mice (Figure 4I). These data demonstrate that RANK expression
on astrocytes facilitates the infiltration of T cells in the spinal cord
during the initial phases of EAE through CCL20 induction,
although CCL20 might also be produced by other cell types.
Pharmacological Inhibition of RANKL Prevents
Development of EAE
We then examined whether EAE can be treated by inhibiting
RANKL signaling. We induced EAE in wild-type mice and treated
themwith the RANKL inhibitor AS2676293, which affects RANKL
signaling and blocks osteoclastogenesis as previously reported1180 Immunity 43, 1174–1185, December 15, 2015 ª2015 Elsevier In(Miyata et al., 2012). Having a molecular weight below 400 Da,
the RANKL inhibitor would be expected to freely diffuse into
the CSF and inhibit RANKL signaling in astrocytes. The mice
were orally administered AS2676293 every other day after
MOG immunization. The RANKL inhibitor effectively delayed
the onset, reduced the severity and the incidence of EAE (Fig-
ure 5A). Treatment with the RANKL inhibitor did not affect the
percentages of Th1 and Th17 cells in the spleen or lymph nodes
(Figure 5B). Notably, treatment with the RANKL inhibitor sub-
stantially reduced the percentages (Figures 5C and 5D) and
the numbers (Figure 5E) of Th1 and Th17 cells infiltrating into
the spinal cord. Among several chemokine ligands, only Ccl20
mRNA expression was reduced in the spinal cord of mice treated
with the RANKL inhibitor (Figure 5F).
Administration of the RANKL inhibitor did not affect the per-
centages or numbers of total Treg cells and pTreg cells (Figures
6A and 6B) and did not alter the frequency, numbers, and activa-
tion status of DCs (Figures 6C and 6D) in the spleen and lymph
nodes of the treated mice. Conversely and consistent with the
phenotype of Tnfsf11flox/D Lck-cre mice, recruitment of inflam-
matory macrophages into the CNS and their expression of
MHC-II were potently suppressed (MFI control mice 3,299 ±
400; RANKL inhibitor-treated mice 1,393 ± 231, p < 0.05), and
the numbers of both microglial cells and macrophages were
strongly decreased (Figures 6E and 6F). These findings show
that pharmacological inhibition of RANKL prevents the infiltration
of pathogenic T cells and autoimmune inflammation in the CNS,
whereas it does not affect DCs and DC-mediated induction of
Treg cells in the secondary lymphoid organs.
Overall, we demonstrated that genetic inactivation of Tnfsf11
in T cells did not affect the immune system in the periphery,
but it potently inhibited infiltration of T cells in the CNS and sub-
sequent local inflammation, thus preventing EAE. Tnfsf11-defi-
cient T cells failed to infiltrate into the CNS parenchyma without
alterations in the secondary lymphoid organs. Mechanistically,
RANKL is essential for the crosstalk between T cells and astro-
cytes constituting the glial layer of the BBB. RANKL on T cells
stimulates the production of CCL20 by RANK-expressing astro-
cytes among other cells, which in turn promotes the infiltration of
CCR6+ T cells into the CNS parenchyma, thus leading to autoim-
mune attack on the CNS.
DISCUSSION
The admittance of T cells across the BBB is a tightly regulated
process and a critical step in autoimmunity of CNS, but its regu-
lation is still incompletely understood. Previous studies showed
that the CCL20-CCR6 axis controls the recruitment of patho-
genic T cells in the CNS during EAE, but it has been unclear
which cell type is the most relevant source of CCL20. Taking
advantage of the T cell-specific Tnfsf11-deficient and astro-
cyte-specific Tnfrsf11a-deficient mice, it was shown that RANKL
on T cells controls the production of CCL20 by astrocytes, which
promotes the recruitment of T cells into the CNS during EAE.
Suppression of EAE by a small chemical RANKL inhibitor
crossing the BBB indicates that RANKL is a potential therapeutic
target for the treatment of CNS autoimmunity.
T cell-specific genetic inactivation of RANKL did not have
any obvious effect on the immune system under homeostaticc.
Figure 5. RANKL Inhibition Suppresses T
Cell Infiltration in the CNS and EAE
(A) EAE score (upper panel) and incidence (lower
panel) of wild-type mice subjected to active EAE
and orally treated with 50 mg/kg of the RANKL
inhibitor or vehicle (arrows indicate time of treat-
ment).
(B and C) Percentage of CD4+ T cells and of IL-17A
and IFN-g producing CD4+ T cells in the spleen
and lymph nodes (B) and in the spinal cord (C) of
MOG-immunized mice treated with the RANKL
inhibitor or vehicle.
(D) Percentage of infiltrated CD4+ T cells in spinal
cord of MOG-immunized mice treated with the
RANKL inhibitor or vehicle.
(E) Numbers of total CD4+ T cells and the indicated
subpopulations in the spinal cord of MOG-immu-
nized mice treated with the RANKL inhibitor or
vehicle.
(F) mRNA expression of chemokine ligands in the
spinal cord of the MOG-immunized mice treated
with the RANKL inhibitor or vehicle. N = 5 per
group. The data are representative of more than
three independent experiments. Mean ± SEM are
shown. *p < 0.05; **p < 0.01; ***p < 0.005; NS, not
significant.conditions, nor did it compromise the ability to generate an
immune response. T cell-specific Tnfsf11 mice normally pro-
duced Th1 and Th17 cells that accumulated in the secondary
lymphoid organs when immunized with MOG peptide, in
agreement with previous literature showing that CD40L can
functionally compensate for the deletion of RANKL in vivo
(Bachmann et al., 1999). Our findings support the data ob-
tained in patients with osteoporosis, in which inhibition ofImmunity 43, 1174–1185, DeRANKL does not increase the occur-
rence of infections (Cummings et al.,
2009). Tnfsf11-deficient T cells normally
differentiated in vivo and in vitro into
Th1 and Th17 cells, secreted normal
amount of interferon-g (IFN-g) and IL-
17A and expressed physiological
amount of the chemokine receptor
CCR6 and the integrins CD29 and
CD49d, suggesting that they have no
intrinsic defects directly affecting their
pathogenicity in the EAE model. They
proliferated normally in vitro and in vivo
and efficiently accessed the secondary
lymphoid organs when adoptively trans-
ferred into recipient mice. Previous re-
ports show RANKL is involved in the
generation of Treg cells (Green et al.,
2002; Loser et al., 2006; Williamson
et al., 2002). Our data suggest that
T cell RANKL do not contribute to the
induction of Treg in EAE (Figure S7). It
is likely that other RANKL-expressing
cell types promote Treg cell differentia-
tion under certain conditions. However,our data demonstrate that all of the Tnfsf11-deficient T cells
subsets we analyzed, including Treg cells, were excluded
from the CNS during EAE. It has been previously reported
that expression of RANKL on thymocytes fosters development
of thymic epithelial cells that negatively select autoreactive
T cells (Akiyama et al., 2008; Hikosaka et al., 2008), but
Tnfsf11flox/D Lck-cre mice did not exhibit any obvious autoim-
mune symptoms.cember 15, 2015 ª2015 Elsevier Inc. 1181
Figure 6. RANKL Inhibition Selectively Targets Inflammatory Cells in the CNS
(A) Percentage of Treg cells in CD4+ T cells (left) and percentage of Helios+ cells in Treg cells (right) in the spleen and lymph nodes MOG-immunized mice treated
with the RANKL inhibitor or vehicle. N = 10 mice per group.
(B) Numbers of Treg cells in the spleen and lymph nodes MOG-immunized mice treated with the RANKL inhibitor or vehicle.
(C) Percentages and activation status of CD11c+MHC-II+ DCs in the spleen and lymph nodes of MOG-immunized mice treated with the RANKL inhibitor or
vehicle. The filled histograms represent the isotype control.
(D) Number of DCs in the spleen and lymph nodes of MOG-immunized mice treated with the RANKL inhibitor or vehicle.
(E) Percentages of F4/80+CD45dimmicroglia and F4/80+CD45hi macrophages and expression of MHC-II onmicroglia (dotted line) andmacrophages (black line) in
the spinal cord of MOG-immunized mice treated with the RANKL inhibitor or vehicle.
(F) Numbers of macrophages and microglia in the spinal cord of MOG-immunized mice treated with the RANKL inhibitor or vehicle. N = 5 per group. The data are
representative of more than three independent experiments. Mean ± SEM are shown. **p < 0.01; ***p < 0.005; NS, not significant.CCR6 is needed for T cells to infiltrate into the CNS and to
induce EAE, as Ccr6/ T cells do not have encephalitogenic
potential (Reboldi et al., 2009). Among the main subpopulation
of spinal cord cells at the onset of EAE, astrocytes expressed
the highest amount of Ccl20, the ligand for CCR6. Because as-
trocytes have been previously reported to express RANK, we
hypothesize that they might be targeted by RANKL on
T cells. Indeed, conditional deletion of RANK from astrocytes
reduced the expression of Ccl20 in the spinal cord and lowered
the infiltration of T cells, thus partially protecting the mice from
EAE. Our data suggest that other cell types might express
CCL20 during the induction phase of EAE. We detected
Ccl20 expression in microglial cells that might contribute to
the residual induction of EAE in Tnfrsf11aflox/D GFAP-ERT2cre
mice.
In this study, we have identified a function of RANKL in
controlling the infiltration of T cells through the BBB. Admin-
istration of a RANKL inhibitor delayed the onset of EAE and
reduced its severity, providing the proof of concept that1182 Immunity 43, 1174–1185, December 15, 2015 ª2015 Elsevier InRANKL is a potential therapeutic target for Th17-mediated
diseases in the CNS. Lymphocyte trafficking has attracted
considerable attention in the treatment of MS due to the
clinical efficacy of recently introduced drugs, including natali-
zumab and fingolimod, which target the migratory activity of
T cells (Pelletier and Hafler, 2012; Ransohoff, 2007). Natalizu-
mab, an anti-a4 integrin antibody, prevents lymphocytes from
crossing the endothelial layer of the BBB, but it targets
Th1 rather than Th17 cells because of the integrin expression
pattern of these cells (Ransohoff, 2007). The high expression
of RANKL in Th17 cells suggests that RANKL inhibition
might preferentially target Th17 than Th1 cells (Sato et al.,
2006) and it might represent a complementary therapeutic
approach. Systemic immunosuppression is an adverse
effect of potent modulators of T cell trafficking (Pelletier
and Hafler, 2012), but inhibition of RANKL does not lead to
peripheral immunosuppression, making this strategy an
auspicious approach to the treatment of autoimmune dis-
eases of the CNS.c.
EXPERIMENTAL PROCEDURES
Mice
Tnfsf11 floxed mice, Tnrfsf11a floxed mice, and Vav-icremice were previously
described (Nakashima et al., 2011) (Hanada et al., 2009) (de Boer et al., 2003).
Lck-cre and GFAP-ERT2cre transgenic mice were obtained from Taconic and
The Jackson Laboratories, respectively. For activation of ERT2cre, 4-hydrox-
ytamoxifen was emulsified in 95% sunflower oil and 5% of ethanol and was in-
jected into each mouse (intraperitoneally [i.p.] 200 mg daily for 4 consecutive
days after weaning). All the mice were maintained in a specific pathogen-
free environment and all the experiments were performed with the approval
of the institutional committee of the University of Tokyo.
Induction of Active EAE
MOG-35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was purchased from
Biologica. 250 mg of MOG peptide were emulsified in complete Freund’s adju-
vant along with 4 mg ml1 ofMycobacterium Tuberculosis H37RA (Difco Lab-
oratories) and subcutaneously injected at the basis of the tail of each mouse.
300 mg of pertussis toxin (Sigma Aldrich) were administered i.p. on day 0, day
2, and day 7 after injection of the emulsion.Mice were scored for EAE everyday
using the following criteria: 0, no clinical signs; 1, limp tail (tail paralysis); 2,
complete loss of tail tonicity and abnormal gait; 3, partial hind limb paralysis;
4, complete hind limb paralysis; 5, death. Mice were analyzed at day17 unless
specified otherwise. At sacrifice, cells were isolated from spleen, peripheral
lymph nodes and spinal cord and further processed.
Mice were deeply anesthetized with pentobarbital sodium salt intraperitone-
ally, then extensively perfused with ice-cold PBS. The lymph axillary, brachial,
and inguinal nodes, spleen, and spinal cord were harvested and cells isolated
using standard methods. The tract of spinal cord contained in the lumbar
vertebrae L4 and L5 was collected and snap frozen for later RNA extraction.
Myelin was separated from the mononuclear cell fraction by centrifugation
on BSA 15% in PBS. For isolation of blood vessel endothelial cells from the spi-
nal cord, pelleted cells were digested for 30 min at 37C in 2 mg/ml collage-
nase. After isolation, cells were washed in Phosphate Buffered Saline, 0.5%
bovine serum albumin and 2 mM EDTA, and then stained with the appropriate
antibodies.
Induction of Passive EAE
Tnfsf11flox/D and Tnfsf11flox/D Lck-cre donor mice were subjected to an induc-
tion of active EAE, as described above. At day 11, cells from the spleen as well
as inguinal, axillary, and brachial lymph nodes were isolated, pooled, and re-
stimulated in vitro in Iscove’s Modified Dulbecco’s Medium (Sigma-Aldrich)
supplemented with 4 mM L-glutamine, 10% FBS, 50 mM 2-ME, 100 U ml1
penicillin and 100 mg ml1 streptomycin and 10 mg ml1 (of) MOG 35-55.
For Th17 polarizing conditions, 50 ng ml1 recombinant IL-23 (R&D) was
added to the culturemedium. For Th1 polarizing conditions, 20 ngml1 recom-
binant IL-12 (Peprotech) and 2 mg ml1 of anti IL-23p19 LEAF antibody (Bio-
legend) were added to the culture medium. After 72 hr at 37C, 5% CO2,
CD4+ T cells were purified using anti CD4 (L3T4) microbeads (Miltenyi Biotec).
Recipient mice were injected with 3 to 63 107 CD4+ T cells depending on the
experiment. Wild-type recipient mice were irradiated at a dose of 400 Gy 1 day
before infusion of the cells. Mice were scored every day for symptoms of EAE,
as described above and analyzed at sacrifice.
Flow Cytometric Analysis
Antibodies conjugated with biotin, FITC, Alexa Fluor 488, PE, PerCP-Cy5.5, al-
lophycocyanin (APC), Alexa Fluor 647, eFluor 450, or Pacific Blue were used at
a 1:200 dilution unless otherwise stated. The following monoclonal antibodies
were purchased from eBioscience: anti-mouse CD3ε (145-2C11), CD4
(RM4-5), CD8 (53-6.7), CD25 (PC61), CD29 (Hmb1.1), CD31 (390), CD45
(30-F11), CD49d (9C10), CD54 (also called ICAM-1) (YN1/1.7.4), CD103
(2E7), CD106 (also called VCAM-1) (429), CD196 (also called CCR6)
(140706), CD205 (205yekta), CD207 (CLEC4K), F4/80 (BM8), MHC class II
(I-A I-E) (M5/114.15.2), T cell receptor-b (TCR-b) (H57-597), Foxp3 (FJK-16
s), Ki-67 (B56), IFN-g (XMG1.2), and IL-17A (eBio17B7). CD11c (HL3), CD86
(GL-1), and T cell receptor-g (TCR-g) (GL3) were purchased from BD Biosci-
ences. Anti-Helios (22F6) was purchased from BioLegend. Foxp3 Staining
Buffer kit (eBioscience) was used for intracellular Foxp3 staining.ImmCytokine Staining
Total cells from the spleen, lymph nodes or spinal cord were stimulated with
50 ngml1 phorbol myristate acetate (Sigma-Aldrich) and 500 ngml1 ionomy-
cin (Sigma-Aldrich) for 5 hr. After 1.5 hr, vesicular trafficking was inhibited by
adding GolgiPlug (BD Biosciences). Cells were stained for surface antigens,
washed, then fixed and permeabilized with IC staining buffer (eBioscience)
for 15 min at room temperature. Labeling of intracellular cytokines was per-
formed using the appropriate monoclonal antibodies diluted in Perm Buffer
1X (eBiosciences). Data were acquired using a FACS Canto II system (BD Bio-
sciences) or a FACS Verse system (BD Biosciences) and data analysis was
performed with FlowJo software (Treestar).
Real-Time PCR
Total RNA was extracted with an RNAeasy mini kit (QIAGEN). Retrotranscrip-
tion into cDNA was performed with Superscript III Retrotranscriptase (Life
Technologies). Quantitative real-time PCR was performed with a LightCycler
(Roche) using SYBRGreen (Toyobo)master mix. The primer sequences are re-
ported in the Table S1. mRNA expression was normalized to that of b-actin
mRNA.
T Cell Differentiation In Vitro
T cells were cultured in Iscove’s Modified Dulbecco’s Medium (Sigma-Aldrich)
supplemented with 4 mM L-glutamine, 10% FBS, 50 mM 2-ME, 100 U ml1
penicillin, and 100 mg ml1 streptomycin. Depending on the experimental con-
ditions, the following reagents were added at the reported concentrations:
10 mg ml1 anti–murine IFN-g (XMG1.2, BD Biosciences), 10 mg ml1
anti–murine IL-4 (11B11, BD Biosciences), 30 ng ml1 recombinant murine
IL-6 (Peprotech), 2.5 ng ml1 recombinant human TGFb (Peprotech), 50 ng
ml1 recombinant murine IL-23 (R&D Systems), 20 ng ml1 recombinant mu-
rine IL-12 (Peprotech), and 2 mg ml1 anti–murine IL-23p19 (MMp19B2,
Biolegend). For T cell polarization, naive T cells were purified using the CD4+
CD62L+ T cell isolation kit II (Miltenyi) and immediately plated in multiwell
plates coated with monoclonal anti-CD3 in the presence of soluble anti-
CD28 for 3 days. For Th17 cell polarization, naive CD4+ T cells were stimulated
in the presence of rmIL-6, rmIL-23, rhTGF-b, anti–IFN-g, and anti–IL-4. For Th1
cell polarization, naive CD4+ T cells were stimulated in the presence of rmIL-12
and anti IL-23p19 antibody. Naive CD4+ T cells stimulated in the presence of
anti–IFN-g and anti–IL-4 were used as Th0 cells.
Isolation of Primary Astrocytes
Brains were collected from newborn mice under a sterile hood and immedi-
ately placed in ice-cold HBSS. Cerebral cortices were isolated from the re-
maining brain tissue, minced in 1 mm3 fragments, and digested in trypsin
0.05% and collagenase 2 mg ml1 for 15 min at 37C. Tissue was then
dissected by pipetting, filtered, and plated on collagen-I coated multiwell
plates in Dulbecco’s Modified Eagle Medium supplemented with 20% Fetal
Calf Serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 50 U ml1 penicillin,
and 50 mg ml1 streptomycin. Cells were cultured for 3–5 passages and
used for coculture when they reached 80% confluence.
Co-culture Experiments
2.5 3 105 Th17 or Th0 cells of the appropriate genotype were added to a 12-
well plate containing 80%-confluent astrocytes. After 48 hr, culture plates
were put on ice and the supernatants were collected for ELISA. T cells were
removed by centrifugation. Adherent astrocytes were lysed in RLT buffer
and RNA was extracted using a RNAeasy micro kit (QIAGEN) following the
manufacturer’s specifications. ELISA for CCL20 (R&D) was performed
following the manufacturer’s instructions with minor modifications.
Administration of the RANKL Inhibitor
The RANKL inhibitor was resuspended in 0.5% methylcellulose (Wako) and
administered to MOG-immunized mice. Mice were orally gavaged with a
soft catheter (Top Corporation). Mice received a dose of 50 mg g1 of a RANKL
inhibitor and control mice an equal volume of 0.5% methylcellulose. Adminis-
tration was repeated every other day starting from day 2 after the induction
of EAE.unity 43, 1174–1185, December 15, 2015 ª2015 Elsevier Inc. 1183
Immunohistochemistry
Samples were embedded in paraffin after overnight fixation in fresh-made 4%
paraformaldehyde in PBS at 4C. Seven mm thin sections were deparaffinized
and rehydrated, then stained with Meyer’s Hematoxylin (Muto Pure Chemical)
and Eosin Y (Wako Chemicals GMBH). For the staining of axonal myelin, rehy-
drated sections were incubated with a solution of Luxol Fast Blue (Sigma
Aldrich) overnight at 57C, washed, rinsed in 0.05% lithium carbonate, stained
in a solution of Cresyl Violet (Sigma Aldrich) for 6 min at 57C, then washed,
dehydrated, and prepared for imaging.
Statistical Analysis
Data are expressed as the mean ± SEM. N = 3 or more per group. Statistical
analysis was performed using the unpaired two-tailed Student’s t test (*p <
0.05; **p < 0.01; ***p < 0.005; N.S., not significant, throughout the paper). Sta-
tistical analysis of EAE incidence was performed using the log-rank test.
Graphs were built using the GraphPad Prism Software. The results reported
are representative of at least three independent experiments.
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